« Return to News | Awards & Advancement

Kite Pharma names chief medical officer

Friday, June 7, 2013 02:10 PM

Kite Pharma, a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT) products for cancer, has appointed Keith Nolop, M.D., chief medical officer. Nolop, with 20 years of drug development experience at both biotechnology and global pharmaceutical companies, was previously senior vice president of development and chief medical officer at Plexxikon.

"Dr. Nolop's vast experience in drug development from conception to approval will be instrumental to advancing Kite's eACT products through multi-center clinical trials and on to registration," said Aya Jakobovits, Ph.D., president and chief executive officer of Kite Pharma.

While at Plexxikon, Nolop was the clinical lead for the development of vemurafenib, a selective inhibitor of mutated BRAF in melanoma co-developed with Hoffman-La Roche and approved worldwide in 2011. He also led the filing of eight IND applications since joining Plexxikon in 2004, including other selective kinase inhibitors in hematological and solid tumor indications.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.